What Is Cetrorelix Used For? Approved Uses, Per the Label

The Approved Indication, Stated Plainly

Cetrorelix is a prescription medicine, not a supplement and not an over the counter product. In the United States it is marketed as Cetrotide (cetrorelix acetate) for injection, a gonadotropin releasing hormone (GnRH) antagonist supplied as a powder for reconstitution and given by subcutaneous injection under medical supervision. The prescribing information carries one indication, worded in substance as the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation. Everything else described below is context for that single indication.

This page is for educational purposes only and is not medical advice; consult a licensed physician or the prescribing clinician managing a fertility cycle about any question concerning cetrorelix. No dosing instructions appear anywhere on this page, and none of the peer reviewed sources cited here reproduce a label revision date, so no revision year is stated.

What the indication describes

During controlled ovarian stimulation for in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI), injectable gonadotropins are given to recruit multiple follicles. Rising oestradiol from those follicles can trigger the pituitary to release LH before the follicles are mature, which can disrupt the planned retrieval. A GnRH antagonist occupies pituitary GnRH receptors competitively and suppresses gonadotropin release rapidly, which is the pharmacological basis for the labelled indication. A 2000 review in Human Reproduction Update described cetrorelix as an LHRH antagonist developed to achieve immediate, dose related suppression of gonadotropin secretion without the initial flare associated with agonists (PMID 10972520).

Approved Indication at a Glance

The Trial Evidence Behind the Indication

Randomised comparisons against GnRH agonists

The clinical case for antagonist based cycles was built largely on head to head randomised comparisons with the long agonist protocols that preceded them. A randomised, multicentre phase IIIb study compared cetrorelix in an oral contraceptive pretreated stimulation cycle with buserelin in IVF and ICSI patients treated with recombinant human FSH (PMID 16537563). A separate prospective, randomised study compared a flexible single dose cetrorelix protocol with a single dose long goserelin protocol and reported comparable effectiveness for IVF cycles (PMID 14653888). Taken together, these randomised comparisons framed the antagonist approach as an alternative to agonist downregulation rather than as an add on (PMID 16537563).

Combination with oral agents in lighter stimulation cycles

Researchers also examined whether an antagonist could be paired with oral ovulation induction agents. One study assessed cetrorelix in combination with clomiphene citrate and gonadotrophins and discussed the approach in the context of a less intensive, so called friendly IVF strategy (PMID 12151431). A separate comparison of mild versus conventional ovarian stimulation in poor responders undergoing IVF or ICSI examined the trade offs between the two stimulation intensities (PMID 28358705). Both lines of work address how the labelled indication is applied in practice, not an expansion of it.

Pooled and network evidence on antagonist protocols

A 2023 systematic review and network meta-analysis in Human Reproduction Update asked what the optimal GnRH antagonist protocol is for ovarian stimulation during assisted reproductive technology treatment, comparing protocol variants across the published randomised evidence (PMID 36594696). That synthesis is useful context because the label defines what the medicine is indicated to do, while the pooled literature explores how antagonist cycles have been structured and compared (PMID 36594696).

Mechanistic work on ovarian and implantation questions

Beyond pituitary suppression, a 2001 article in Human Reproduction examined the ovarian actions of GnRH antagonists and their relationship to embryo implantation, a question raised as antagonist protocols entered wider assisted reproduction practice (PMID 11278203). A 2024 comparative analysis of GnRH peptide antagonist chemistry and formulation discussed how structural and formulation differences within the class carry implications for clinical safety and efficacy (PMID 39861098).

Regulatory History of the Indication

Cetrorelix reached clinical use as part of a wider effort to replace agonist downregulation with direct receptor blockade in assisted reproduction. The 2000 review in Human Reproduction Update summarised the preclinical and early clinical development of cetrorelix as an LHRH antagonist at the point when the compound was moving into reproductive medicine (PMID 10972520). Randomised comparative work continued after marketing, including the randomised multicentre phase IIIb comparison with buserelin in recombinant FSH stimulated IVF and ICSI cycles (PMID 16537563) and the randomised flexible single dose cetrorelix versus long goserelin study (PMID 14653888).

The indication itself has stayed narrow. Across the cited literature, the approved role remains confined to preventing premature LH surges during controlled ovarian stimulation, and subsequent publications refined protocol choice rather than widening the indication (PMID 36594696). More recently, attention has turned to whether orally active antagonists could serve a similar role; one study described relugolix, an orally active GnRH antagonist, as a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation (PMID 34938148). That line of research concerns other molecules and does not alter the cetrorelix label.

Tolerability and Safety Signals in the Cited Literature: What Studies Report

Safety information for any prescription medicine sits in its prescribing information and in the judgement of the clinician who prescribes it. The peer reviewed sources cited here add class level context rather than a complete adverse event list.

• A 2024 comparative analysis of GnRH peptide antagonists examined chemistry and formulation differences across the class and discussed their implications for clinical safety and efficacy (PMID 39861098).
• An animal study reported that triptorelin and cetrorelix induced immune responses and affected uterine development as well as expression of ESR1, LHR and FSHR genes and proteins in mice (PMID 27075695). Findings in mice do not transfer directly to clinical practice.
• The 2000 review of cetrorelix summarised tolerability observations alongside the pharmacology available at that time (PMID 10972520).
• Comparative randomised work against agonist protocols reported on cycle outcomes in IVF and ICSI populations (PMID 14653888).

Anyone weighing risks and benefits in a specific situation should raise them with the prescribing clinician, who has access to the full label and the individual medical history.

Areas Studied That Are Not Approved Indications

One short factual note, kept separate from the approved use. Published research has examined GnRH antagonists in uterine fibroids, with a 2025 meta-analysis assessing the efficacy of GnRH antagonists in that setting (PMID 39821450), and a 2025 laboratory study reported that cetrorelix promoted cell apoptosis via the PI3K-AKT-FOXO1 pathway in epithelial ovarian cancer models (PMID 41458598). These are research findings only. Neither uterine fibroids nor any oncology indication is an approved use of cetrorelix, and preclinical results of this kind are not treatment recommendations.

How to Read the Label Versus the Literature

1. The label defines the approved use. For cetrorelix that is inhibition of premature LH surges during controlled ovarian stimulation, and nothing broader.
2. Randomised trials support the indication. Comparisons against agonist protocols sit behind it (PMID 16537563, PMID 14653888).
3. Meta-analyses refine protocol questions. A network meta-analysis compared antagonist protocol variants within the same indication (PMID 36594696).
4. Mechanistic and animal work is background. Ovarian and implantation questions (PMID 11278203) and murine findings (PMID 27075695) inform research, not labelling.
5. Individual decisions belong to a clinician. Whether cetrorelix fits a particular cycle is a medical judgement, made with the prescribing physician.

Related Reading

For a broader look at how safety evidence is assembled across peptide compounds, see Are Peptides Safe? on PeptideU.

References

• The LHRH antagonist cetrorelix: a review (Human Reproduction Update, 2000)
• Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists (Human Reproduction, 2001)
• Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'? (Human Reproduction, 2002)
• Comparable effectiveness using flexible single-dose GnRH antagonist (cetrorelix) and single-dose long GnRH agonist (goserelin) protocol for IVF cycles (Reproductive BioMedicine Online, 2003)
• Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with r-hFSH: a randomized, multicentre, phase IIIb study (Human Reproduction, 2006)
• Triptorelin and cetrorelix induce immune responses and affect uterine development and expressions of genes and proteins of ESR1, LHR, and FSHR of mice (Immunopharmacology and Immunotoxicology, 2016)
• Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing IVF/ICSI (In Vivo, 2017)
• A novel orally active gonadotropin-releasing hormone antagonist, relugolix, is a potential substitute for injectable GnRH antagonists in controlled ovarian stimulation in assisted reproductive technology (Reproductive Medicine and Biology, 2022)
• What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis (Human Reproduction Update, 2023)
• GnRH Peptide Antagonist: Comparative Analysis of Chemistry and Formulation with Implications for Clinical Safety and Efficacy (Pharmaceuticals, 2024)
• Efficacy of GnRH antagonists in the treatment of uterine fibroids: a meta-analysis (Archives of Gynecology and Obstetrics, 2025)
• Cetrorelix promotes cell apoptosis via the PI3K-AKT-FOXO1 pathway in epithelial ovarian cancer (Frontiers in Oncology, 2025)